99Tcm-labelled chimeric human/mouse anti-granulocyte antibody bone marrow scintigraphy: a preliminary clinical study.
Bone marrow scintigraphy using 99Tcm-labelled chimeric anti-granulocyte antibody (anti-NCA-95) was performed in 17 patients with haematological disorders and skeletal metastases. Chimeric anti-NCA-95 antibody (chNCA95 Ab, 0.2 mg) labelled with 444 MBq 99Tcm was administered to obtain bone marrow images 4 h post-injection. One week later, an 111In-chloride bone marrow scan was performed on nine patients with haematological disorders. Lumbar bone marrow-to-background (L/B) and ilium-to-background (I/B) uptake ratios were calculated for each scan. In six patients with suspected skeletal metastases, 99Tcm-HMDP bone scans were performed. No patient had any adverse reaction or any immune reaction over 20 weeks. In the patients with haematological disorders, the L/B and I/B ratios of the 99Tcm-chNCA95 Ab scan were 3.41 +/- 0.90 and 1.23 +/- 0.31, whereas those of the 111In-chloride scan were 1.58 +/- 0.32 and 1.00 +/- 0.32, respectively. In assessing findings of irregular central bone marrow uptake and peripheral expansion of the bone marrow, the 99Tcm-chNCA95 Ab scan was much better than the 111In-chloride scan. In the six patients with suspected skeletal bone metastases, three true-positive and two true-negative results were observed. This preliminary study has revealed that 99Tcm-chNCA95 Ab scanning is safe and useful in the diagnosis of haematological disorders and skeletal metastases.
Higuchi
T
T
Department of Nuclear Medicine, Gunma University School of Medicine, Japan.
Inoue
T
T
Sarwar
M
M
Oriuchi
N
N
Karasawa
M
M
Naruse
T
T
Yamanaka
H
H
Watanabe
T
T
Chung
J K
JK
Endo
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000951:Antigens, Neoplasm / Q000009:adverse effects; D001772:Blood Cell Count; D001774:Blood Chemical Analysis; D001853:Bone Marrow / Q000000981:diagnostic imaging*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D015815:Cell Adhesion Molecules; D005260:Female; D006402:Hematologic Diseases / Q000000981:diagnostic imaging; D006801:Humans; D007553:Isotope Labeling; D008297:Male; D008562:Membrane Glycoproteins / Q000009:adverse effects; D051379:Mice; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D011993:Recombinant Fusion Proteins / Q000009:adverse effects; D013667:Technetium
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; D008562:Membrane Glycoproteins; D019275:Radiopharmaceuticals; D011993:Recombinant Fusion Proteins; D013667:Technetium